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Abstract
Background: Forequarter amputation (FQA) is a surgical treatment of tumors in the upper extremity and shoulder
girdle that infiltrate the neurovascular bundles. In both curative and palliative settings, FQA can serve as an effective
oncological treatment.
Methods: This study presents the FQA-related data of 30 patients (mean age 50 years) treated between 2000
and 2012. Their medical condition was high-grade bone or soft tissue sarcoma in 26 and high-grade carcinoma in four
cases.
Results: Mean operation time was 119 min. One major and five minor complications occurred in the postoperative
period. Resection margins were wide in 91 % of patients. Local recurrence was observed in four patients after
19 months on average. Patients treated with curative intention had a 5-year survival chance of 39 %. Average
survival after palliative amputation was 11 months.
Conclusions: FQA provides an opportunity for adequate oncological margins in large tumors, while offering
relief from tumor-induced distress in palliative situations.
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Background
In most cases of primary and secondary musculoskeletal
tumors, a limb salvage procedure for local treatment is
available. Therefore, few tumors require an amputation
[1]. While amputations of the lower extremity can be
sufficiently compensated by exoprostheses [2, 3], the
psychological and physiological impact of a forequarter
amputation (FQA) on the patient is significant. However,
only a small number of tumors around the shoulder
girdle infiltrating the nerve and vessel bundle require
this type of amputation to achieve sufficient oncological
margins in a curative or even in a palliative setting. Al-
though FQA is an extensive operation, oncologically satis-
fying results are achievable [4, 5]. The use of exoprostheses
to regain the functions of the lost arm, however, is not very
common among patients. Typically, only a shoulder gab is
applied to cosmetically restore the shoulder contour.
The goal of the present study was to develop a clinical
guideline, what type of patients benefit from FQA. To
that end, we compiled data from 30 patients who under-
went an interscapulothoracic resection in our institution
during the past 12 years. We analyzed these FQAs in
regard to perioperative risks and oncological outcome.
Methods
Between 2000 and 2012, we performed FQA in 30 pa-
tients (11 females, 19 males) suffering from high-grade
malignancies of the shoulder girdle (Table 1). Their me-
dian age at FQA was 50 years (range 8–83 years). FQA
was performed in case of locally recurrent tumor in 17
patients and for primary tumor manifestation in 13
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Table 1 Patient-related synoptical table

















1 m 32 es OS y st II B n iT c n 58 101 AWD
2 f 77 OS n b II B n iT c n n 3 DOD
3 f 72 OS y b II B n TR c n n 136 NED
4 f 19 OS y b III B n TR c y (lung) n 72 DOD
5 m 16 OS n b II B y iT c n n 132 NED
6 m 19 OS n b III B y iT c y (lung) n 2 LOF
7 m 55 Lung cancer n b Single bone metastasis n iT c y n 195 NED
8 m 19 OS y b III B n TR c y (lung) n 13 DOD
9 f 63 DD CS y b III B y iT c y (lymph node) 2 60 DOD
10 f 64 MFG G III y b II B n TR c n n 5 DOD
11 m 32 OS n b II B y iT c n n 17 DOD
12 f 10 OS y b III B y iT c y (lung) n 109 NED
13 f 69 NOS G III n st II B n iT c n n 58 NED
14 m 57 Liposarcoma G III n st II B n iT c n n 38 DOD
15 m 32 Hemagioendothelioma y b II B n TR c n n 91 NED
16 m 43 MFH G III y st II B n TR c n n 8 DOD
17 f 35 CS G III n b II B n iT c n n 2 LOF
18 f 76 MFH G III y st II B n TR c n 11 26 DOD
19 m 74 Liposarcoma G III y st II B n TR c n n 31 DOD
20 m 73 CS G II y st III B n TR c y (lymph node) n 25 DOD
21 m 66 NOS G III y st III B n TR c y (lung) n 41 NED
22 f 16 OS n b III B y iT c y (lung, bone) n 10 DOD
23 m 8 OS n b III B y iT c y (bone) n 9 DOD
24 m 37 Fibrosarcoma G III y st II B n TR c n 4 18 DOD
25 m 76 MFH G III y st III B n TR p y (lung) n 19 DOD
26 m 74 MFH G III y st III B n TR p y (lung) n 15 DOD
27 m 83 Squamous cell carcinoma y st Multiple metastases n TR p y (lymph node, lung) n 1 DOD
28 m 53 Synovial sarcoma G III y st III B n TR p y (lung) n 21 DOD
29 f 70 Merkel cell carcinoma y st Multiple metastases n TR p y (lymph node) n 10 DOD
30 m 82 Squamous cell carcinoma y st Multiple metastases n TR p y (lymph node) n 17 NED
OS osteosarcoma, es OS extraskeletal osteosarcoma, DD CS dedifferentiated chondrosarcoma, st soft tissue, b bone, iT initial surgery, TR tumor recurrence, c curative, p palliative, DOD dead of disease, AWD alive with













patients. Tumor stage according to the Enneking staging
system [6] was stage IIB in 14 and stage III in 12 pa-
tients. Three patients showed an advanced metastatic
stage of carcinoma, and one patient suffered from a large
single bone metastasis of a bronchial carcinoma. Fifteen
patients had a primary soft tissue tumor, whereas 15
patients had a primary bone involvement of the prox-
imal humerus and/or the scapula. Pathological fracture
of the humerus was present in seven patients at the time
of initial diagnosis. Six of them were osteosarcoma and
one chondrosarcoma (Table 1). Thoracic-wall infiltration
was present in two patients (Fig. 1a, b). In both cases, a
partial thoracic-wall resection was performed in addition
to the FQA, and defect closure was achieved by a devita-
lized porcine skin graft. Resection margins were catego-
rized as wide, marginal, or intralesional, following the
Enneking classification based on the histopathological
examination of the specimen [7]. The mean residence
time in hospital was 19.5 days (range 9–59 days). In all
cases but one, postoperative observation on intermediate
or intensive care unit was necessary. All but one patient
with bone and soft tissue sarcoma received chemother-
apy. Overall, 18 patients underwent additional local
radiotherapy; 28 patients had a median follow-up of
42 months (range 1–195 months) after FQA (Table 1).
Median follow-up after initial diagnosis was 68 months
(range 3–292 months). Two patients were unavailable to
follow up after their discharge from the hospital. Both
patients returned abroad to their home countries (2 months
after FQA).
The Short Form (36) Questionnaire (SF-36) question-
naire was used to evaluate the postoperative functional
and psychological results after FQA; it was also available
for the nine surviving patients.
The postoperative pain level was measured on a six-
step scale according to the SF-36 questionnaire (1-none,
2-very, 3-mild, 4-moderate, 5-severe, 6-very severe) and
was available for 27 of the patients.
Results
The average duration of surgery was 119 min (range 36–
240 min). Patients with primary tumor manifestation
had a shorter operation time than patients with recurrent
tumor (108 vs. 126 min). The mean amount of blood
transfusion needed was 1.1 packed blood cells (PBC)
(range 1–6). There was no difference observed between
primary and recurrent tumors. Primary wound closure
was achieved in all patients.
Regarding the overall surgical risk of the FQA, we ob-
served one major and five minor complications in the
perioperative setting. Also, there was no intraoperative
complication noticed. The major complication was seen
in a patient who developed a pneumothorax with con-
secutive respiratory insufficiency after additional partial
thoracic-wall and lung resection. The patient needed in-
tensive care unit (ICU) treatment for 2 weeks. However,
this 77-year-old patient did not recover and died 3 months
after surgery due to generally weak condition. The minor
complications were delayed wound healing and the need
of surgical local debridement in all five patients. However,
wound closure was achieved for all patients at the latest
follow-up. Four of the five wound complications occurred
after initial local radiation therapy.
Initial postoperative treatment of pain was realized by
continuous interscalene brachial plexus block with Bupiva-
caine 0.175 % in all patients [8]. Postoperative phanthom
pain and/or local pain were observed in all patients. An
average pain intensity of 3.07 on the six step scale was per-
ceived. Although most of the patients required the daily
use of per oral analgetic drugs, only 28 % (8/28) suffered of
moderate (5/28) or even more intensive pain (3/28).
Fig. 1 a, b MRI T1 with gadolinium enhancement (3a coronal plane/3b axial plane) imaging of a 77-year-old female with a radiotherapy-induced
osteosarcoma of the glenoid (37 years after breast cancer treatment). The MRI shows the infiltration of the thoracic wall and a tumor encasement
of the brachial vessel/nerve bundle
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The evaluation of the SF-36 questionnaire presented
fair results in terms of psychological and functional out-
come. The mean mental condition parameter (MCS)
was 47.7 (range 25.5–61.2), and the functional parameter
(PCS) was less favorable with a mean PCS of 37.7 (range
13.7–54.8) as expected.
Only two of the nine surviving patients are using a
shoulder gap on a regular basis, and one patient uses a
myoelectric arm exoprosthesis with a satisfying function
(Fig. 2). The other six patients did not use any device.
Three of the other 19 patients used a shoulder gap regu-
larly, and 3 others were using a cosmetic arm replace-
ment only.
Regarding the oncological outcome, the patients are
divided into two treatment groups, depending on the
underlying treatment intention. Before FQA, a curative
treatment strategy was set in 24 patients (80 %) and 6
patients (20 %) were classed to be palliative. Overall
survival differed significantly (p = 0.041) between these
two groups (Fig. 3).
Curative group
Single metastasis at the time of FQA was observed in 9
(37.5 %) of the 24 patients with a curative treatment
goal. All of them underwent resection of the pulmonary
and lymph node metastasis, so that the intent of treatment
was defined curative; 88 % received additional chemother-
apy and 50 % local irradiation. Twelve of these 24 patients
had newly diagnosed tumors, and 7 of them had a patho-
logical fracture of the proximal humerus at the time of
initial diagnosis. In the other 12 patients, FQA was per-
formed because of recurrent tumor. In the curative treat-
ment group, wide resection margins were achieved in
most patients (22/24) and marginal resection margins in
two patients (9 %). Two patients were unavailable for
potential follow-up.
Local recurrence of the tumor occurred in four patients
(16 %) after an average 19 months (range 1–58 months)
post FQA. All four were treated with the FQA because of
recurrent tumor after previous local tumor excision. None
of the patients that were treated primarily with the FQA
experienced a local relapse; 14 patients (58 %) died of dis-
ease after an average 24 months (range 3–72 months)
following FQA. One patient is still alive with disease (pul-
monary metastasis) 101 months after treatment. The other
seven patients are without evidence of disease at the
latest follow-up (on average, 103 months after FQA and
134 months after initial diagnosis).
Regarding the oncological outcome in terms of local
recurrence or survival, there was no statistically signifi-
cant difference observed between patients affected by
initial tumor versus recurrent tumor. Five-year survival
was 39 % for all patients subject to curative treatment.
For patients with primary tumor manifestation, the 5-
year survival was 43.6 % and for recurrent tumor 34.1 %
(p = 0.204) (Fig. 4).
Palliative group
All six patients classified as palliative had a recurrent
tumor and multiple non-resectable metastases at the time
of FQA. In this subgroup, one to four local tumor surgeries
were performed prior to FQA. The mean time from initial
surgical treatment to final FQA was 37 months (range
2–112 months). Local tumor exulceration (Fig. 1a, b)
and untreatable pain as well as malfunction or dysfunc-
tion of the arm due to tumor infiltration were motiva-
tions to perform FQA in all of these patients. In this
group, resection margins were wide in three, marginal
in one, and intralesional in two cases. All six patients
received local irradiation after FQA, although four pa-
tients had already received local radiation treatment
after their initial surgery. Interestingly, none of them
Fig. 2 35-year-old patient using a myoelectric exoprosthesis after
FQA because of a recurrent hemangioendothelioma
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Fig. 3 Cumulative survival related to treatment intention
Fig. 4 Cumulative survival in the curative treatment group related to primary vs. recurrent tumor presentation
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developed another local recurrence until the follow-up.
However, after an average of 11 months (range 1–
21 months), 83 % (5/6) of treated patients died of
disease.
Discussion
As the patient population underlying this study was
small, highly selective, and heterogeneous in terms of
the entity (primary bone and soft tissue tumors, carcin-
oma metastasis), tumor stage, and clinical presentation,
the results are difficult to compare with published data.
Therefore, we present key findings of our series in con-
sideration of the surgical procedure and the oncological
usefulness to develop a clinical guideline for selecting
patients that may benefit from FQA. FQA needs to be
considered as a treatment option in oncological surgery
in highly selected cases and in a variety of high-grade
soft tissue and bone sarcomas, and even in metastasis of
carcinoma. For patients under curative or palliative
treatment intention, FQA provides the opportunity of
achieving wide oncological resection margins, also in
difficult tumor presentations as described in this study
and in the literature [5, 9–11].
Surgery-related complications
An average surgery time of 119 min and the requirement
of less than an average of two PBC (range 0–6) prove
the low surgical risk even for critically ill patients. These
findings are comparable to the results presented in
literature [9, 12, 13]. Further, the low occurrence of
major (3 %) and minor complications (13 %) confirms
the reliability of this procedure. Similar frequencies of
complications are described in a study by Baghia et al.
[12], who report 20 % procedure-related complications,
including three wound healing complications and one
pleural effusion.
Function
As FQA has a massive impact on the psychological and
functional integrity of the patient, the potential risks
must be carefully weighed against the values of this op-
eration for each patient. We saw a curative treatment
intention in 80 % of the patients included in this study,
even if they had a solitary metastasis at the time of FQA,
or for patients with recurrent tumor manifestation of
high grade sarcoma. Despite the reduced prognosis of
these particular patients, we agreed to maximum surgi-
cal and oncological treatment, in order to seize the op-
portunity of cure, even if it was expected to be small. In
this curative concept, wide resection margins, resection
of all tumor manifestation, and additional chemo- and/or
radiotherapy are indispensable. In 91 % of the curative
group, wide resection margins according to Enneking
were achieved. Further, a 5-year survival chance of 43 %
for patients with primary tumors and 34 % for patients
with recurrent tumors underlines the benefits of this treat-
ment concept for selected patients—something which has
also been shown in previous studies [9, 12]. For instance,
Baghia et al. [12] report 30 % survival for curatively
treated patients in which a curative treatment option was
only set for patients without metastasis at the time of
FQA. Qadir et al. [11] reasoned: “In a select group of pa-
tients, FQA remains a relatively safe a reliable procedure
for curative or palliative treatment of upper extremity
malignant disease, when other less radical options has
failed.” The group of six patients with a pathological frac-
ture of a primary osteosarcoma presented an ambivalent
oncological outcome. Although the pathological fracture
is a clearly negative prognostic factor for survival and local
recurrence [14, 15], we observed no local recurrence. Four
patients died of metastatic disease. Two patients were
alive without evidence of disease after a mean follow-up of
59 months after FQA. These results seem to support the
decision of performing a FQA in these particular patients
to achieve local tumor control and maintain the chance of
cure under difficult conditions.
Despite adequate oncological margins in more than
90 % of patients, we observed a local recurrence of 16 %
(4/24) in the curative treatment group, which is disap-
pointingly high. This can be explained by the fact that
all four patients suffering of a local relapse had had pre-
vious tumor surgery. In these cases, a wide oncological
margin is more difficult to achieve due to the potential
tumor cell contamination of the surrounding tissue and
possible undetected lymph node metastasis caused by
previous surgical treatment. However, it should be ac-
knowledged that none of the patients treated initially
with a FQA experienced a local relapse. Other authors
have reported local recurrence frequencies of 18 % and
up to 35 % after FQA [5, 9], demonstrating the difficulty
of local tumor control in these particular patients.
Palliative group
In contrast to a curative treatment intention, in which
maximum treatment is imperative, the selection of pa-
tients with a palliative tumor condition has to be reconsid-
ered even more critically. FQA may reduce tumor-related
complications like pain, functional impairment, or tumor
exulceration, but will not improve survival. In this study,
all but one of the palliatively treated patients died within
11 months after the operation. Based on these results
from a palliative setting, FQA should only be considered,
if all other treatment options, such as radiotherapy, have
been attempted [11].
FQA should be used to reduce the tumor-related dis-
tress and improve quality of life, which was achieved for
all palliative patients in our series. In fact, this precondi-
tion is widely accepted; for example, Wittig et al. [13]
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presented eight patients in their study, which received a
FQA with palliative intention. They all had severe, pro-
nounced pain and a useless extremity due to the tumor
expansion before surgery. All these patients experienced
significant pain relief and improvement in quality of life
after FQA. Although the average patient’s survival was
5.5 months (range 3–12 months) after surgery, they con-
cluded that the FQA would be an adequate therapy [13].
In contrast to this result, Daigeler et al. [9] performed a
study with patients who had preexisting pain before
proximal major amputations. They reported persisting
pain after operative treatment at different intensity for
all patients except one [9]. Pain relief via amputation
was achieved in 46 % of the treated patients only. A not-
able fraction of 41 % would not agree to undergo this
surgical procedure again. This problem is in line with
our own study results. We also observed persistent post-
operative pain at varying intensity. However, all palliatively
treated patients were relieved of the local tumor-related
distress after the FQA. The satisfying SF-36 results sup-
port this conclusion. Obviously, the physical status classi-
fication (PSC), representing the physical status after FQA,
was limited compared to other types of amputation. The
mental status represented by the average mental status
classification (MSC) value was comparable to patients suf-
fering the loss of the lower extremity [16, 17].
Conclusions
FQA provides not only a safe and reliable treatment op-
tion for patients with high-grade bone and soft tissue
malignoma in primary but also recurrent tumor manifest-
ation. The perioperative risks are low, and adequate onco-
logical margins are achieved regularly. However, with
respect to the strong impact, the indication for a FQA has
to be evaluated on an individual basis. Despite the fact
that palliative amputations reduce tumor-related distress,
it should remain a last-resort treatment.
Abbreviations
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